MYELOMATCH: Screening Study for Myeloid Cancer Treatment Options

Program Overview

The MYELOMATCH study is designed to help people with myeloid cancer, such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), find the best treatment options. By testing bone marrow and blood samples, doctors can identify specific markers that indicate which treatments might work best. This information helps match patients to clinical trials or standard treatments that target their type of cancer. If no specific trial is available, patients continue with standard care while remaining eligible for future trials.

Description

The MYELOMATCH study involves several steps to help find the best treatment for people with myeloid cancer:

1. Screening and Reassessment: Patients provide bone marrow and blood samples for testing. These tests look for specific markers that can guide treatment decisions. Results are organized quickly to match patients with suitable clinical trials or standard treatments.

2. Tier Advancement Pathway (TAP): If no specific trial is available, patients continue with standard care but remain eligible for future trials as new options become available.

3. Treatment Options: Patients may be assigned to different treatment groups based on their specific cancer type and risk level. These groups test various combinations of chemotherapy and other drugs to find the most effective treatment.

4. Ongoing Monitoring: Throughout the study, patients undergo regular tests, including bone marrow and blood sample collection, to monitor their response to treatment and adjust as needed.

The study aims to improve treatment outcomes by using personalized approaches based on each patient's unique cancer profile.

Eligibility Criteria

Locations